Shareholder Alert: Ademi LLP investigates whether LogicBio® Therapeutics, Inc. has obtained a Fair Price in its transaction with AstraZeneca

Provided By PR Newswire

Last update: Oct 3, 2022

MILWAUKEE, Oct. 3, 2022 /PRNewswire/ -- Ademi LLP is investigating LogicBio (NASDAQ: LOGC) for possible breaches of fiduciary duty and other violations of law in its transaction with AstraZeneca.